Can-Fite BioPharma (CANF) Tops Q1 EPS by 63c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. BA
4. STX
5. NXPI
6. SPY
7. NOW
8. GOOGL
9. KIDS
10. GOOG

Go back to Can-Fite BioPharma (CANF) Tops Q1 EPS by 63c, Revenues Miss

Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update

June 1, 2020 7:00 AM EDT

Company to host conference call at 8:30 a.m. ET today, June 1 Achieved efficacy and safety endpoints in Phase II NASH trial, with all cases of NASH significantly resolved after 12 weeks of treatment with 25 mg Namodenoson Pre-IND filed with FDA for clinical study of Piclidenoson in treatment of COVID-19 Interim results from Phase III Piclidenoson trial for psoriasis and rheumatoid arthritis expected Q4 2020

PETACH TIKVA, Israel--(BUSINESS... More